2026 Suzuki Swift Ultra Mhev 1.2L Hybrid electric · HT26 YBC

The official DVSA MOT record for this 2026 Suzuki Swift Ultra MHEV contains no test entries whatsoever, so no roadworthiness history can be established from the data provided. With the vehicle being only months old at the time of evaluation in August 2026, the absence of any MOT pass or failure is not in itself a red flag, as the first test would not normally be due until the vehicle reaches three years of age. However, this does mean there is no verifiable mechanical baseline against which a buyer can compare wear rates or component durability. The maintenance trend cannot be classified as stable, worsening, or improving because no outcomes exist to plot. Mileage context is similarly absent. The recorded figure is listed as unknown, and there are no prior readings to calculate annual accumulation or identify unusual gaps. For a near-new 2026 model, this simply means the vehicle has not yet accumulated enough service life to generate a mileage pattern through MOT testing. A prudent buyer would therefore need to rely entirely on the in-person odometer reading and any accompanying dealer or manufacturer documentation, as the DVSA file offers no independent mileage verification at this stage. Once the vehicle reaches MOT age, key areas worth scrutinising on this model line include the rear suspension coil springs and bushes, which are commonly flagged on small Suzuki hatchbacks, along with front brake disc wear and any binding caliper symptoms that develop with urban use. The mild-hybrid electrical ancillaries, including the 12V auxiliary battery under the bonnet and the integrated starter-generator belt drive, should be checked for warning lights or unusual starting behaviour. Given that the model is still early in its production cycle, structural corrosion should not yet be a concern, but a close visual inspection of the underbody, exhaust mounting, and tyre shoulder wear remains worthwhile. Without a recorded MOT pass, however, any assessment remains speculative rather than evidence-based. Buying score: 50. Risk level: Medium.